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Tribbles family of pseudokinase proteins are known to mediate the degradation of target proteins in 
drosophila and mammalian systems. The main protein proteolysis pathway in eukaryotic cells is the 
ubiquitin proteasome system (UPS). The TRIB2 mammalian family member has been well 
characterised for its role in murine and human leukaemia, lung and liver cancer. One of the most 
characterised substrates for TRIB2-mediated degradation is the myeloid transcription factor CCAAT 
enhancer binding protein  (C/EBP). However, across a number of cancers, the molecular 
interactions that take place between TRIB2 and factors involved in the UPS are varied and have 
differential downstream effects. This review summarises our current knowledge of these interactions 





TRIB2 gene dysregulation in Cancer 
Tribbles homolog 2 (TRIB2) is a pseudokinase that functions as a molecular adaptor mediating 
degradation and changes to signalling cascades[1]. TRIB2 is also shown to be a potent oncogene in a 
variety of malignancies, including myeloid[2] and lymphoid[3] leukaemia, melanoma[4], lung cancer[5], 
and liver cancer[6]. The oncogenic activity of TRIB2 is linked to its dysregulated expression, rather 
than its dysregulation via mutation in the majority of cancers. We analysed TRIB2 gene in the 
Catalogue Of Somatic Mutations In Cancer (COSMIC) database (http://cancer.sanger.ac.uk, [7], the 
most comprehensive source of curated analysed somatic mutations in human cancer to date. This 
analysis has allowed us determine whether TRIB2 is altered at the genomic level across a panel of 
tumour samples identified by the tissue of origin. From a total number of 23983 unique tumour 
samples, 86 were found with missense (51%), synonymous (46%), nonsense (2%) and inframe 
deletion (1%) mutations in TRIB2 (Fig. 1A). Interestingly, although the overall point mutation rate is 
low, tumours with documented roles for TRIB2 oncogene such as malignant melanoma and lung 
cancer do have detectable TRIB2 point mutations. In tissues matching Acute Myeloid Leukaemia 
(AML), which has a very strong association with TRIB2 oncogenic activity, no mutations were 
retrieved from COSMIC curated data provided by scientific literature and resequencing results from 
the Cancer Genome Project at the Wellcome Trust Sanger Institute (1/1942 haematopoietic and 
lymphoid tissue samples identified with a TRIB2 mutation corresponded to a Multiple Myeloma 
patient sample). Indeed no mutations have been found in ~ 75 AML samples analysed by exome 
sequencing with good coverage across all exons (Ross Levine, personal communication). 
Interrogation of other genomic alterations affecting TRIB2 in the COSMIC database identified 
subsets of tumour tissues with TRIB2 overexpressed (Fig. 1B). Overall the frequency rate for these 
alterations is higher and includes lung, skin, liver and hematopoietic and lymphoid tissues samples. Of 
note, 4/9 samples overexpressing TRIB2 in the Haematopoietic and lymphoid tissues matched AML 
samples. Given that there is strong evidence for TRIB2 oncogenic function in these tumours, these 
analyses suggest that elevated TRIB2 expression has potential implications in other tumour tissue 
contexts yet to be explored e.g. endometrium (endometrioid carcinoma), central nervous system 
(astrocytoma grade V), prostate and large Intestine samples (both matching adenocarcinoma). Other 
TRIB2 gene alterations include copy number variation (CNV), which albeit rare, are found across 
different tumours tissues and mainly associated with increased copy number (all except for breast, 
thyroid and kidney which showed CNV loss) (Fig.1C). Hypermethylation, associated with chromatin 
silencing, was found exclusively in prostate and large intestine tumour tissues (Fig. 1D). Together 
these analyses suggest that TRIB2 oncogenic activity is related to its elevated gene expression rather 
than associated with different genomic alterations or mutations.  
It is important to understand how TRIB2 gene expression is regulated given its elevated expression in 
cancer. TRIB2 gene expression has been shown to be regulated by a number of genes in normal and 
malignant haematopoietic cells, including Notch1[8], MEIS1[9], E2F1 and C/EBP[10], GATA2 and 
FOG1[11], PITX1[12] and TAL1/E protein complex[3]. A number of microRNAs also regulate the 
expression levels of TRIB2, including but not limited to miR-511, miR-1297[13], miR-99[14,15], miR-
155[16], and let-7[17]. An example of how TRIB2 expression is regulated in AML has been shown 
where E2F1 cooperates with the C/EBP p30 oncogenic isoform to activate the TRIB2 promoter in 
AML cells. Indeed, wild type C/EBP p42 is bound to the TRIB2 promoter in normal granulocyte 
macrophage progenitor (GMP) cells. This study detailed the feedback loop between TRIB2, C/EBP 
p42 and p30, and E2F1 that contributes to AML cell growth and survival[10]. The central mechanism 
of TRIB2-induced AML identified in this study is based on specific TRIB2-C/EBP interactions, 
with C/EBP being a key substrate of TRIB2 induced proteasomal degradation. The proteasomal 
mediated degradation of TRIB substrates and interaction with proteins of the ubiquitin proteasome 
system (UPS) are central to TRIB function in a number of cancers and will be discussed further.  
TRIB2: the ruler of E3 ubiquitin ligase activities 
The degradation of damaged or no longer necessary proteins is mainly regulated by the UPS. The 
targets of this pathway are marked by the addition of a ubiquitin tag. Ubiquitin is a short peptide 
covalently bound to a lysine (Lys) residue on the target. This complex protein modification requires 
the activity of at least three enzymes: an E1 ubiquitin activating enzyme, an E2 ubiquitin conjugating 
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enzyme and an E3 ubiquitin ligase. The E3 ligase family comprise over 1000 enzymes with different 
substrate specificities. Moreover homologous ubiquitin like proteins (UBL) and deubiquitinases 
(DUBs), which hydrolyse ubiquitin moieties, represent additional layers of regulation for the 
proteolysis of specific targets[18]. In addition to the 26S proteasome complex, an immunoproteasome 
complex is present in cells of haematopoietic origin and potentially relates to the higher sensitivity of 
proteasome inhibition in leukaemic cells[19].  
The first connections between TRIB and protein degradation functions were identified in drosophila, 
where drosophila tribbles was shown to promote degradation of its targets; String (homologous of the 
mammalian CDC25 phosphatase, positive regulator of cell cycle progression) and slow border cells 
(Slbo) (promoter of cell migration and homologous of the human C/EBP)[20]. The members of the 
C/EBP family of transcription factors are involved in regulation of differentiation in many tissues and 
control proliferation through interaction with cell cycle proteins. In the haematopoietic system 
C/EBP acts as a tumour suppressor that promotes cell cycle arrest and induces granulocytic 
differentiation through inhibition of E2F activity[21,22]. Both mammalian TRIB1 and TRIB2 have been 
shown to retain the degradative functions toward the C/EBP protein and promote C/EBP p42 
degradation and this function underlies their oncogenic potential in leukaemia[2,23,24]. Moreover, 
TRIB2-dependent C/EBP p42 degradation is mediated by the proteasome and constitutive 
photomorphogenesis 1(COP1). COP1 is an E3 ubiquitin ligase recruited by TRIB2 for the interaction 
with C/EBP, suggesting TRIB2 functions as a scaffold protein to colocalise the enzyme with its 
target[25]. The COP1 binding site in the C-terminus is conserved among the TRIB family of proteins 
and indeed COP1 is the E3 ligase responsible for TRIB1-mediated degradation of C/EBP[23] and 
TRIB3-mediated degradation of acetyl-coenzyme A carboxylase (ACC) in fasting condition[26]. 
TRIB2 also regulates C/EBP protein levels in liver cells, and mediates C/EBP degradation in lung 
cancer models[5,6]. In the latter case, the E3 ligase TRIM21 was identified to function in TRIB2-
mediated C/EBP degradation. With regard to specific TRIB2 substrates, another member of the 
C/EBP family, C/EBPβ, has been shown to be degraded by TRIB2 in adipogenesis. In this study, 
TRIB2 functions as a negative regulator of adipogenesis associated with Akt inhibition[27]. Another 
example of TRIB-dependent degradation of target proteins in cancer is represented by Activating 
transcription factor 4 (ATF4) which occurs during hypoxia in human tumour cells overexpressing 
TRIB3[28]. Interestingly, the murine ortholog of TRIB3 Neuronal cell death-inducible putative kinase 
(NIPK) has also been associated with downregulation of ATF4 transcriptional activity, but in absence 
of proteolytic degradation[29]. The protein interaction of ATF4 with TRIB2 or TRIB1 as not been 
reported. 
Cell context, especially with regard to protein-protein interactions is highly relevant in deciphering 
the function of many signalling molecules, including TRIB proteins. TRIB2 has been implicated as a 
positive or negative mediator of proteasomal degradation. For example, TRIB2 interacts with the 
substrate binding subunit of the ubiquitin complex SKP1-CUL1-F-box βTrCP in liver cancer cells[6]. 
This complex is responsible for Yes-associated protein (YAP) degradation, but TRIB2 binding on 
βTrCP subunit leads to YAP stabilization and transactivation of YAP target genes. The C-terminal 
domain of TRIB2 was shown to be responsible for the interaction with βTrCP in these liver cancer 
cells. Noteworthy in the same study, TRIB2 also targets C/EBP for degradation, but this was not via 
βTrCP E3 ligase. As previously discussed, COP1 or TRIM21 are known to mediate TRIB2 dependent 
C/EBP degradation in AML and lung cancer, whereas the E3 ligase has not been clarified in liver 
cells. TRIB2 and the E3 ligase Smad ubiquitination regulatory factor 1 (SMURF1) also interact in 
liver cancer cells. SMURF1 is the enzyme responsible for TRIB2 ubiquitination and proteasomal 
dependent degradation and SMURF1 inhibition triggers TRIB2-dependent carcinogenesis in the 
liver[30]. Nonetheless, TRIB2 is also a partner of SMURF1 in the inhibition of the Wnt signalling 
effector β-catenin and TCF4. Indeed, deletion of the SMURF1 binding sites on the TRIB2 protein 
abolished its ability to downregulate β-catenin and transcription factor 4 (TCF4)[31]. COP1 or βTrCP 
were also described as additional modulators in this same pathway[32]. Together these data reveal the 
complexity of TRIB2 and UPS interactions in liver cancer cells, and highlight the importance of cell 
context in TRIB family protein function. 
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UPS aberration in leukaemia 
Dysregulation of E3 ligase enzymatic activity has been reported in different malignancies. 
Transforming mutant variants of the E3 ubiquitin ligase Casitas B-Lineage Lymphoma proto-
oncogene (cClb) have been found in human myeloid malignancies and all these mutations were 
associated with loss of E3 ubiquitin ligase activity in addition to a malignant gain of function[33]. 
Mutations in the E3 ligase FBW7 have been associated with oncogenic signalling mechanisms in 
different cancers including NOTCH1 activation in T-ALL[34]. Moreover, the recent profiling of the 
somatic mutation landscape of epigenetic regulators in paediatric cancer identified the deubiquitinase 
USP7 as one of the most frequent mutations in T-ALL[35]. This DUB is associated with chromatin 
remodelling and it is referred as an “eraser” among epigenetic modifiers. It’s physiological function is 
to stabilize the histone H2B (as well as other targets), removing ubiquitin subunits from the substrates. 
In 8% of T-ALL cases sequence variation translates to loss of function of the protein and the 
consequent epigenetic alteration is associated with the leukaemic disease[35]. This case supports the 
important role of ubiquitination signalling beyond terminal protein degradation in leukaemic 
transformation. The proteolytic pathways of UPS and autophagy in AML cell lines are directly 
involved in the response to chemotherapeutic drugs cytarabine and doxorubicin. Studies show that the 
response to chemotherapy is highly dependent on the basal level of activation of the UPS in 
leukaemic cells [36]. It is possible to measure the proteasome expression and activities in the plasma of 
AML, ALL and MDS patient samples and higher levels of UPS protein and activities are detectable in 
patients plasma samples[37]. Importantly, the levels of proteasome activities can be used to risk stratify 
for the prognosis of different blood tumours. Since it is likely that the activities detected in the AML 
patients’ plasma is reflecting the activities in the leukaemic cells, screening of the proteasome 
activities in the plasma samples from patients could be advantageous not only as a biomarker, but also 
to identify the most suitable therapeutic combination taking advantage of the new drugs available in 
clinical trials targeting the UPS system. 
Targeting UPS in blood tumours 
Proteasome inhibitors 
Leukaemic cells express high levels of proteasomes[38] and this is likely one of the reasons why 
therapeutic proteasome inhibition has shown better results in blood cancers than in solid tumours[39]. 
Multiple toxicity mechanisms of proteasome inhibition have been validated in preclinical studies. 
These comprise NFkB inhibition through stabilization of its regulator IkB; cell cycle arrest due to 
deregulation of cyclins and other cell cycle regulator proteins; induction of a proapoptotic state 
through stabilization of p53 and Bax and downregulation of Bcl-2; ROS production; transmembrane 
mitochondrial potential gradient dissipation; aggresome formation; endoplasmic reticulum (ER) and 
unfolded protein response (UPR)[40]. 
Eight classes of proteasome inhibitors (PI) have been recognised across natural compounds and 
synthetic molecules (peptide aldehydes, peptide vinyl sulfones, syrbactins, peptide boronates, peptide 
’β’-epoxyketones, peptide ketoaldehydes, β-lactones,and oxatiazol-2-ones). Only representative 
members of some classes have reached the stage of clinical trials investigations in cancer. Many have 
failed due to lack of specificity and or toxicity in preclinical studies. The main PIs of interest in the 
treatment of haematological malignancies include three peptide boronates, two peptide epoxyketones 
and one marine natural product, b-lactone. The boronate compound Bortezomib (BTZ) is a reversible 
inhibitor of the proteasome and the immunoproteasome and the first PI ever entered in clinical 
trials[41]. BTZ is currently approved for used as single agent or in combination therapies in multiple 
myeloma or mantle cell lymphoma patients. Moreover a number of clinical trials have been assessing 
its efficacy in aggressive disease like acute leukaemias (CALGB (Alliance) Study 10502, COG 
AAML 1031)[42]. To overcome toxicity and resistance challenges with BTZ, a great effort has been 
spent in the design and characterization of next generation inhibitors. Among them Carfilzomib has 
been approved by the FDA for the treatment of relapsed/refractory multiple myeloma[43], and 
Oprozomib, Ixazomib, Marizomib and Delanzomib have already reached clinical trials investigation. 
The activity of immunoproteasome specific inhibitors is also currently being assessed in preclinical 
investigation in models of immunological disorders[41]. 
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Other UPS targets 
The recent interest in targeting the UPS system has brought attention to the identification of druggable 
targets upstream of the proteasome, which by their nature are predicted to lead to more specific 
inhibition and fewer side effects. In this category there are E1 activating enzyme inhibitors, E2 
conjugating enzyme inhibitors, E3 ubiquitin ligases inhibitors and DUB enzyme inhibitors[44]. Indeed 
the inhibition of the UBL modifier Nedd8 is currently in clinical trials for AML and MDS[45]. More 
than one E3 ligases have been chosen as potential targets in the drug discovery process for treatment 
of haematological malignancies and many small molecules have been studied. Examples among the 
most targeted E3 ligases are MDM2, involved in p53 regulation[46], and SCF (Skp1-Cullin-Fbox) 
multi-subunit E3 ligases[47]. 
Concluding remarks and Future perspective 
Given that C/EBP stability is tightly regulated at molecular level and that TRIB2 mediated 
dysregulation of this pathway is linked to AML, liver and lung carcinogenesis, targeting the related 
network of E3 ligases could open new exciting therapeutic windows, resulting in a more specific and 
possibly more effective treatment of these malignancies. There is an urgent need for alternative 
therapeutic strategies in the treatment of blood diseases. Increasing interest has been raised around the 
modulation of proteolytic pathways such as autophagy and UPS, which often play critical roles in 
cancer cells. TRIB2, as a signalling pathway modulator and binding partner of different E3 ubiquitin 
ligase enzymes has gained attention over the past decade as a major regulator in solid tumours and 
different leukaemia subtypes. TRIB2 has been proposed as a valid biomarker for diagnosis and 
progression of melanoma, correlating higher TRIB2 expression levels with advanced stages of the 
disease[48]. Given the strong preclinical data regarding TRIB2 in AML, the screening of TRIB2 
protein expression in leukaemia patients would be extremely useful to complement the current 
information available on TRIB2 carcinogenesis and mutational profile.  
 
Figure 1. Genomic alterations in TRIB2 gene. (A) Histogram presentation of point mutations in 
TRIB2 gene in tumour samples using the COSMIC database (top). Pie chart referring to the frequency 
of missense (51%), synonymous (46%), nonsense (2%) and deletion inframe (1%) point mutations in 
the identified tumour samples (lower). (B) Histogram presentation of gain of TRIB2 gene expression 
in the tumour samples indicated. Among them 4/9 Haematopoietic and lymphoid tissues samples 
match AML as part of the Acute Myeloid Leukaemia study (COSU377) from The Cancer Genome 
Atlas [TCGA] in which over expression is defined after a z-score>2. (C) Histogram displaying tumour 
tissues where copy number variations (CNV) of the TRIB2 gene was identified, with the respective 
frequency in tumour samples. (D) Histogram presenting tumour tissues where hypermethylation of the 
TRIB2 gene locus was identified and respective frequency. Data was retrieved by v72 of COSMIC 
database (http://www.sanger.ac.uk) and only tissues displaying TRIB2 alterations are shown. NS*, not 
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